List view / Grid view
8 June 2018 | By Dan Appledorn (Director of US Biology - Essen Bioscience)
The Nobel Prize-winning observations and discoveries of John B. Gurdon and Shinya Yamanaka have ignited an explosion of excitement around the potential use of stem cells in research and treatment of human disease.
8 June 2018 | By Tecan
This webinar, supported by Tecan, focused on the automated assessment of liver and cardiac toxicities in lead optimisation, using biochemical and human iPS cell assays.
7 June 2018 | By Liz Quinn (Associate Director - Stem Cells Marketing at Takara Bio USA)
Human primary hepatocytes (hpheps) are the gold standard for in vitro evaluation of drug metabolism, drug-drug interactions, and metabolic disease research. However, hpheps don’t survive in standard 2D culture for very long – no longer than two or three days.
7 June 2018 | By Dr. Paul Wylie (Head of Applications at TTP Labtech)
For most people, traditional High-Throughput Screening (HTS) represents large automation rigs and large libraries of small molecules screened against drug targets, however, the development of biological therapeutics has been gaining considerable pace for many reasons.
7 June 2018 | By Drug Target Review
The General Data Protection Regulation (GDPR) is a new set of EU rules governing how a company manages, protects and administers personal data. Whether you are a subscriber, author, advertiser or supplier to our journal, we may hold information about you and we need to keep it private and secure.
6 June 2018 | By Laura Goldie - Head of Technical Services - Biogelx Ltd.
Despite their vast therapeutic potential in such areas as cell therapy and tissue engineering, stem cells have yet to live up to their original hype and demonstrate widespread clinical success.
6 June 2018 | By Joseph Zock (Senior Director - Product Management - IntelliCyt -a Sartorius Company)
The demand for new therapeutics is driving efforts to discover novel antibodies and harness their power in both biologics and adoptive cell therapy areas.
6 June 2018 | By Sesha Tekur (Key Accounts Manage/Field Application Specialist at Thermo Fisher Scientific)
For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.
5 June 2018 | By Philip Spencer (AstraZeneca)
Advances in genomics and structural biology are providing drug discovery scientists with more biological targets to prosecute, and greater information about each one.
5 June 2018 | By Shahzad Ali - Senior Scientist -Plasticell Ltd
Regenerative medicine has emerged as one of the major areas of modern medical therapy. Its primary objective is to restore or establish normal function through the regeneration or replacement of diseased cells, tissues or entire organs. There are a variety of methods and approaches by which this can be achieved.…
5 June 2018 | By Tobias Pusterla (International Marketing Manager at BMG Labtech)
Sometimes the difference between identifying a partial or super agonist is only the time point at which the binding reaction is measured.
4 June 2018 | By Steven G Jarvis (Head of Pharma & Biotech Segment Strategy - MilliporeSigma)
The pursuit of improved R&D productivity rates coupled with decreased cycle times has dominated pharmaceutical discourse in recent years.
4 June 2018 | By Eleen Shum (Manager - R&D Genomics Applications - BD)
Target the genes that matter for efficient sequencing and analysis with custom-targeted gene panels.
4 June 2018 | By Drug Target Review
Bioactivity profiling has been traditionally used to assess the selectivity of new drug candidates in the context of target-based approaches, where pharmacological selectivity is a key requirement.
1 June 2018 | By Drug Target Review
This In-Depth Focus reviews the history of cancer treatments, looks at improving the translation of disease biology though phenomics, and considers how to enhance cell bioprocessing through cell-based combinatorial culture.
Send this to a friend
Follow: